2 results
Approved WMOCompleted
Primary Objective:To assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL by:_characterizing the dose limiting toxicities (DLT) and (S)AEs…
Approved WMOCompleted
HV cohort 1Primary Objectives* To characterize the local tolerability of topical bimiralisib after 21 days* To characterize the systemic PK of topical bimiralisib after 21 daysSecondary Objective* To characterize the safety of topical bimiralisib…